No headlines found.
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results
Globe Newswire (Mon, 13-Jan 8:00 AM ET)
Globe Newswire (Mon, 6-Jan 8:00 AM ET)
Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference
Globe Newswire (Wed, 27-Nov 8:00 AM ET)
Apyx Medical Corporation to Attend 15th Annual Craig-Hallum Alpha Select Conference
Globe Newswire (Tue, 12-Nov 4:05 PM ET)
Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
Globe Newswire (Fri, 8-Nov 7:05 AM ET)
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Apyx Medical trades on the NASDAQ stock market under the symbol APYX.
As of January 29, 2025, APYX stock price climbed to $1.46 with 14,802 million shares trading.
APYX has a beta of 1.93, meaning it tends to be more sensitive to market movements. APYX has a correlation of 0.10 to the broad based SPY ETF.
APYX has a market cap of $54.96 million. This is considered a Micro Cap stock.
Last quarter Apyx Medical reported $11 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $107,000 and exceeded earnings estimates by $.05.
In the last 3 years, APYX traded as high as $11.67 and as low as $.97.
The top ETF exchange traded funds that APYX belongs to (by Net Assets): VTI, VXF, IWC, DFAC.
APYX has underperformed the market in the last year with a price return of -35.7% while the SPY ETF gained +24.9%. However, in the short term, APYX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +15.0% vs +4.0% return in SPY. But in the last 2 weeks, APYX shares have been beat by the market, returning +2.1% compared to an SPY return of +3.4%.
APYX support price is $1.33 and resistance is $1.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APYX shares will trade within this expected range on the day.